Wednesday, March 28, 2012
Morphotek Inc., of Exton, Pa., completed enrollment in a Phase III trial (FAR-131) of farletuzumab for ovarian cancer. The randomized, double-blind trial will compare farletuzumab at two doses in combination with second-line standard of care against standard of care and placebo with a primary endpoint of progression-free survival.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.